Free tool
FAERS Monitor: Implanon
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021529 or its brand name (Implanon, Etonogestrel). Reports on generic versions are filed under their own applications.
Reports
57,570
Serious
13,734
24% of reports
Hospitalization
1,706
Death reported
110
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event12,139
- product quality issue6,915
- complication associated with device6,622
- device breakage5,381
- incorrect product administration duration5,033
- complication of device insertion4,758
- device difficult to use4,584
- complication of device removal4,373
- unintended pregnancy3,743
- device deployment issue3,686
- pregnancy with implant contraceptive3,434
- vaginal haemorrhage3,434
- implant site pain3,247
- device dislocation2,893
- amenorrhoea2,545
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 34 |
| 2007 | 88 |
| 2008 | 56 |
| 2009 | 56 |
| 2010 | 3 |
| 2011 | 55 |
| 2012 | 619 |
| 2013 | 2,766 |
| 2014 | 3,778 |
| 2015 | 4,243 |
| 2016 | 4,828 |
| 2017 | 4,427 |
| 2018 | 4,941 |
| 2019 | 4,845 |
| 2020 | 3,976 |
| 2021 | 3,817 |
| 2022 | 3,505 |
| 2023 | 1,626 |
| 2024 | 1,477 |
| 2025 | 1,819 |
| 2026 | 10,610 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,996,589 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pregnancy with implant contraceptiveSignal | 3,434 | 994.0 | 932.3 | 914,336 |
| implant site painSignal | 3,247 | 965.9 | 905.0 | 857,781 |
| complication associated with deviceSignal | 6,622 | 305.2 | 295.7 | 1,093,626 |
| unintended pregnancySignal | 3,743 | 203.2 | 195.4 | 483,810 |
| device deployment issueSignal | 3,686 | 147.7 | 142.3 | 382,419 |
| complication of device removalSignal | 4,373 | 116.2 | 112.4 | 379,049 |
| complication of device insertionSignal | 4,758 | 114.5 | 110.9 | 407,638 |
| incorrect product administration durationSignal | 5,033 | 110.2 | 106.9 | 418,669 |
| amenorrhoeaSignal | 2,545 | 61.8 | 59.3 | 130,303 |
| device breakageSignal | 5,381 | 55.7 | 54.2 | 251,067 |
| vaginal haemorrhageSignal | 3,434 | 31.3 | 30.3 | 92,921 |
| device difficult to useSignal | 4,584 | 27.1 | 26.3 | 107,607 |
| no adverse eventSignal | 12,139 | 26.2 | 25.7 | 276,456 |
| device dislocationSignal | 2,893 | 26.0 | 25.0 | 64,949 |
| product quality issueSignal | 6,915 | 19.5 | 19.1 | 116,216 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.